Found: 32
Select item for more details and to access through your institution.
Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 11, p. 1212, doi. 10.1002/cpdd.1451
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies.
- Published in:
- Cephalalgia Reports, 2023, v. 6, p. 1, doi. 10.1177/25158163231191582
- By:
- Publication type:
- Article
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2013, v. 5, n. 3, p. 113, doi. 10.1177/1759720X13483894
- By:
- Publication type:
- Article
Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study.
- Published in:
- Journal of Pain Research, 2014, v. 7, p. 679, doi. 10.2147/JPR.S70200
- By:
- Publication type:
- Article
Results of switching to milnacipranin fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study.
- Published in:
- Journal of Pain Research, 2013, v. 6, p. 311, doi. 10.2147/JPR.S43395
- By:
- Publication type:
- Article
Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystonia.
- Published in:
- Movement Disorders, 1994, v. 9, n. 6, p. 626, doi. 10.1002/mds.870090608
- By:
- Publication type:
- Article
Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis.
- Published in:
- Movement Disorders, 1994, v. 9, n. 4, p. 441, doi. 10.1002/mds.870090411
- By:
- Publication type:
- Article
The dopamine motor system.
- Published in:
- Movement Disorders, 1989, v. 4, n. S1, p. S38, doi. 10.1002/mds.870040506
- By:
- Publication type:
- Article
Localization of D-2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography.
- Published in:
- Nature, 1986, v. 323, n. 6085, p. 267, doi. 10.1038/323267a0
- By:
- Publication type:
- Article
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 6, p. e2215499, doi. 10.1001/jamanetworkopen.2022.15499
- By:
- Publication type:
- Article
Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.
- Published in:
- Arthritis Research & Therapy, 2013, v. 15, n. 4, p. R88, doi. 10.1186/ar4268
- By:
- Publication type:
- Article
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
- Published in:
- Cephalalgia, 2023, v. 43, n. 1, p. 1, doi. 10.1177/03331024221128250
- By:
- Publication type:
- Article
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
- Published in:
- Cephalalgia, 2022, v. 42, n. 1, p. 3, doi. 10.1177/03331024211042385
- By:
- Publication type:
- Article
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
- Published in:
- Cephalalgia, 2021, v. 41, n. 5, p. 546, doi. 10.1177/0333102420970523
- By:
- Publication type:
- Article
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1412, doi. 10.1111/head.14631
- By:
- Publication type:
- Article
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 8, p. 1135, doi. 10.1111/head.14619
- By:
- Publication type:
- Article
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 322, doi. 10.1111/head.14433
- By:
- Publication type:
- Article
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 1, p. 79, doi. 10.1111/head.14439
- By:
- Publication type:
- Article
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 3, p. 422, doi. 10.1111/head.14089
- By:
- Publication type:
- Article
Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 4, p. 686, doi. 10.1111/head.13766
- By:
- Publication type:
- Article
Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 1, p. 141, doi. 10.1111/head.13682
- By:
- Publication type:
- Article
Atogepant: Mechanism of action, clinical and translational science.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 1, p. 1, doi. 10.1111/cts.13707
- By:
- Publication type:
- Article
Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials.
- Published in:
- Neurology & Therapy, 2021, v. 10, n. 1, p. 235, doi. 10.1007/s40120-021-00234-7
- By:
- Publication type:
- Article
Mortality in Levodopa-Treated Parkinson's Disease.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Mortality in Levodopa-Treated Parkinson's Disease.
- Published in:
- Parkinson's Disease (20420080), 2014, p. 1, doi. 10.1155/2014/426976
- By:
- Publication type:
- Article
Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene.
- Published in:
- Annals of Neurology, 2000, v. 47, n. 4, p. 517, doi. 10.1002/1531-8249(200004)47:4<517::AID-ANA17>3.0.CO;2-B
- By:
- Publication type:
- Article
Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations.
- Published in:
- Annals of Neurology, 1998, v. 44, n. 1, p. 10, doi. 10.1002/ana.410440107
- By:
- Publication type:
- Article
Maternal inheritance in Parkinson's disease.
- Published in:
- Annals of Neurology, 1997, v. 41, n. 2, p. 265, doi. 10.1002/ana.410410218
- By:
- Publication type:
- Article
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
- Published in:
- Movement Disorders, 2008, v. 23, n. 15, p. 2177, doi. 10.1002/mds.22095
- By:
- Publication type:
- Article
Fatal encephalitis in a patient with refractory celiac disease presenting with myorhythmia and carpal spasm.
- Published in:
- Movement Disorders, 2007, v. 22, n. 3, p. 407, doi. 10.1002/mds.21324
- By:
- Publication type:
- Article